After 16 years, BMS' megablockbuster cancer drug finally runs into its first generic competition
First approved by the FDA in 2006, Bristol Myers Squibb’s cash cow cancer drug Revlimid on Monday began seeing competition for the first time with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
